Evidence map›Paper›PMID 39992723›Full record

ArticleFuture oncology (London, England)2025

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.

Paul Leger, Stanley Frencher, Jones T Nauseef, Brian Jones, Mehmet A Bilen, Alan Brown, Aminha Ullah, Shane McDevitt, Che-Kai Tsao

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07128927 (Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07128927 narecruitingnot on this map

Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors

TypeinterventionalSponsorGeorgetown UniversityRan2025 to 2026Enrolled40ConditionsInsomniaArmsSleep Healthy Using the Internet (SHUTi), Patient education
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul LegerDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Stanley FrencherDepartment of Urology, David Geffen School of Medicine, University of California, MLK Jr. Community Health, Los Angeles, CA, USA.
Jones T NauseefDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-2302-4171
Brian JonesPennsylvania Prostate Cancer Coalition, Harrisburg, PA, USA.
Mehmet A BilenDepartment of Hematology and Medical Oncology, Genitourinary Medical Oncology Program Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Alan BrownAdvocate Radiation Oncology, Fort Myers, FL, USA.
Aminha UllahBayer Healthcare Pharmaceuticals, Whippany, NJ, USA.
Shane McDevittBayer Healthcare Pharmaceuticals, Whippany, NJ, USA.
Che-Kai TsaoTisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to partner with patients, advocates, and physicians to better understand the barriers that exist for Black and African Americans to enroll in prostate cancer (PCa) clinical trials. PATIENTS &

methodsThrough moderated discussions with patients, advocates, and physicians, we identified potential opportunities to increase the enrollment of underrepresented patients in PCa clinical trials.

resultsWe identified key barriers to Black and African American enrollment in PCa clinical trials that were shared by all groups but also identified group-specific barriers. We developed recommendations based on key themes that have the potential to increase the enrollment of Black and African Americans in PCa clinical trials.

conclusionsWhile racial diversity in PCa clinical trials remains an unsolved problem, there are significant opportunities to better address this unmet need. Through a multi-perspective approach to identify key barriers that limit Black and African American enrollment in PCa clinical trials, we developed recommendations for both sponsors and clinical trial sites to increase diverse patient enrollment in PCa clinical trials, with a focus on employing practical strategies.

Indexed as

Black or African AmericanClinical Trials as TopicPatient ParticipationPatient SelectionProstatic NeoplasmsHumansMaleclinical trial participation barriersMinority clinical trial participationpatient authorshippatient engagementpatient involvementpatient participationprostate cancerurologic/prostate

Identifiers

PMID39992723
PMCPMC11938956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.